Stroke
Conditions
Interventions
Case series:N/A
Sponsors
The first hospital attached to Suzhou University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Men aged 18-80 years old or non-pregnant, non-lactating women of childbearing age (No surgery and birth control during a year in post-menarche to menopause) have a negative pregnancy test at screening and during the study and after study drug was last used within a month to take a reliable contraceptive measures (Such as oral contraceptives or contraceptive implants; Reliable barrier method of contraception (Containing contraceptive diaphragm or cervical cap, contraceptive foam containing condoms, intrauterine device); Partner ligation of the vas deferens or abstinence) or non-women of childbearing age (Has been more than a year of menopause); 2. TIA initial onset with symptoms and signs remitted completely in 24h, while no responsibility infarct imaging; 3. Ischemic stroke that onset first or past with the modified Rankin Scale (mRS) more than 2 points onset again; onset within 48 hours, consistent with acute ischemic stroke standards and confirmed by neuroimaging; 4. Patients who need to receive antiplatelet therapy; 5.Patients agreed to accept the program and signed informed consent; 6.The history of data collection and the follow-up process can be saved .
Exclusion criteria
Exclusion criteria: 1. fainting patients; 2. intracranial hemorrhage or subarachnoid hemorrhage; 3. atrial fibrillation and other cardiogenic cerebral embolism; 4. Severe disability, severe end-stage disease; 5. Patients with antiplatelet therapy contraindications; 6. Patients with more serious heart, liver, kidney dysfunction, total bilirubin 1.5 times more than the upper limit of normal, AST or ALT 1.5 times more than the upper limit of normal; 7. Associated with lung infection, or severe systemic infected; 8. History of serious allergic reactions or two or more kinds of food or drug allergies, and within six months of various immunization history; 9. Other organic disease of the brain caused by intracranial hypertension symptoms, such as people with brain tumors; 10. Patients with serum HIV-positive, syphilis antibody positive, hepatitis B, hepatitis C or other severe infectious diseases; 11. Patients with severe mental illness, cognitive dysfunction, or patients can not be understood and signed the informed consent; 12. Coagulation disorders; 13. Patients who were intended to use anticoagulant therapy or thrombolytic therapy; 14. Other antiplatelet drugs out of the test (including medicine) used; 15. Uncontrolled high blood pressure, blood pressure after treatment higher than 180/110mmHg; severe diabetes (late complications occur) failed to control the disease after treatment; impact of physical activity associated with other diseases function before treatment associated with claudication, osteoarthritis, rheumatoid arthritis, gouty arthritis and other disorders caused by physical activity may affect the nervous or functional checks; 16. Patients participated in other clinical researchers within three months; 17. Judged by a doctor, there are other conditions exist that patients are not suitable for clinical studies; 18. Patients who were undergone surgery and trauma (including fractures) within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet aggregation rate;coagulation functio; | — |
Countries
China
Contacts
Public ContactQi fang
Outcome results
None listed